Analysis of HLA-DRB1 polymorphisms in Japanese patients with primary biliary cirrhosis (PBC): The HLA-DRB1polymorphism determines the relative risk of antinuclear antibodies for disease progression in PBC

Hepatology Research

Volumn 40, Issue 5, 2010, Pages 494-504

  Nakamura, Minoru ^a,b,c   Yasunami, Michio ^d   Kondo, Hisayoshi ^b   Horie, Hitomi ^d   Aiba, Yoshihiro ^a   Komori, Atsumasa ^a,b   Migita, Kiyoshi ^a,b   Yatsuhashi, Hiroshi ^a,b   Ito, Masahiro ^a,b   Shimoda, Shinji ^e   Ishibashi, Hiromi ^a,b  

^a NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^b NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^c National Hospital Organization   (Japan)

^d NAGASAKI UNIVERSITY   (Japan)

^e KYUSHU UNIVERSITY   (Japan)

Author keywords

Anti centromere antibodies; Anti gp210 antibodies; HLA DRB1*0405; HLA DRB1*0803; HLA DRB1*1502; Primary biliary cirrhosis

Indexed keywords

ANTINUCLEAR ANTIBODY; CENTROMERE ANTIBODY; GLYCOPROTEIN GP 210 ANTIBODY; HLA DR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ANTIBODY BLOOD LEVEL; ARTICLE; DISEASE COURSE; DNA POLYMORPHISM; FEMALE; GENETIC PREDISPOSITION; GENETIC RISK; GENOTYPE; HUMAN; JAPANESE; JAUNDICE; MAJOR CLINICAL STUDY; MALE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 77954357113     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2010.00631.x     Document Type: Article

References (42)

1. Scheuer PJ. Primary biliary cirrhosis. Proc R Soc Med 1967, 60:1257-60.
2. Rubin E, Schaffner F, Popper H. Primary biliary cirrhosis. Am J Pathol 1965, 46:387-407.
3. Leung PSC, Coppel RL, Ansari A, Munoz S, Gershwin ME. Antimitochondrial antibodies in primary biliary cirrhosis. Semin Liver Dis 1997, 17:61-9.
4. Courvalin JC, Worman HJ. Nuclear envelope protein autoantibodies in primary biliary cirrhosis. Semin Liver Dis 1997, 17:79-90.
5. Invernizzi P, Selmi C, Ranftler C, Podda M, Wesierska-Gadek J. Antinuclear antibodies in primary biliary cirrhosis. Semin Liver Dis 2005, 25:298-310.
6. Makinen D, Fritzler M, Davis P, Sherlock S. Anti-centromere antibodies in primary biliary cirrhosis. Arthritis Rheum 1983, 26:914-17.
7. Invernizzi P, Podda M, Battezzati PM. Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. J Hepatol 2001, 34:3g66-72.
8. Muratori P, Muratori L, Ferrari R. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroenterol 2003, 98:431-7.
9. Nakamura M, Shimizu-Yoshida Y, Takii Y. Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis. J Hepatol 2005, 42:386-92.
10. Wesierska-Gadek J, Penner E, Battezzati PM. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology 2006, 43:1135-44.
11. Nakamura M, Kondo H, Mori T. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 2007, 45:118-27.
12. Nakamura M, Komori A, Ito M. Predictive role of anti-gp210 and anti-centromere antibodies in long-term outcome of primary biliary cirrhosis. Hepatol Res 2007, 37:S412-419.
13. Nishimura Y, Oiso M, Fujisao S. Peptide-based molecular analysis of HLA class II-associated susceptibility to autoimmune diseases. Intern Rev Immunol 1998, 17:229-62.
14. Shiina T, Inoko H, Kulski JK. An update of the HLA genomic region, locus information and disease associations. Tissue Antigens 2004, 64:631-49.
15. Gregersen PK, Behrens TW. Genetics of autoimmune diseases-disorder of immune homeostasis. Nat Rev Genet 2006, 7:917-28.
16. Juran BD, Lazaridis KN. Genetics and genomics of primary biliary cirrhosis. Clin Liver Dis 2008, 12:349-65.
17. Underhill J, Donaldson P, Bray G, Doherty D, Portmann B, Williams R. Susceptibility to primary biliary cirrhosis is associated with the HLA-DR8-DQB1*0402 haplotype. Hepatology 1992, 16:1404-8.
18. Begovich AB, Klitz W, Moonsamy PV. Genes within the HLA class II region confer both predisposition and resistance to primary biliary cirrhosis. Tissue Antigens 1994, 43:71-7.
19. Wassmuth R, Depner F, Danielsson A. HLA class II markers and clinical heterogeneity in Swedish patients with primary biliary cirrhosis. Tissue Antigens 2002, 59:381-7.
20. Donaldson P, Agarwal K, Craggs A. HLA and interleukin 1 gene polymorphisms in primary biliary cirrhosis: associations with disease progression and disease susceptibility. Gut 2001, 48:397-402.
21. Donaldson PT, Baragiotta A, Heneghan MA. HLA class II alleles, genotypes, haplotypes and amino acids in primary biiary cirrhosis: a large-scale study. Hepatology 2006, 44:667-74.
22. Mella JG, Roschmann E, Maier K-P, Volk BA. Association of primary biliary cirrhosis with the allele HLA-DPB1*0301 in a German population. Hepatology 1995, 21:398-402.
23. Seki T, Kiyosawa K, Ota M. Association of primary biliary cirrhosis with human leukocyte antigen DPB1*0501 in Japanese patients. Hepatology 1993, 18:73-8.
24. Onishi S, Sakamaki T, Maeda T. DNA typing of HLA class II genes; DRB1*0803 increases the susceptibility of Japanese to primary biliary cirrhosis. J Hepatol 1994, 21:1053-60.
25. Mukai T, Kimura A, Ishibashi H. Association of HLA-DRB1*0803 and *1602 with susceptibility to primary biliary cirrhosis. Int Hepatol Comm 1995, 3:207-12.
26. Invernizzi P, Battezzati PM, Crosignani A. Peculiar HLA polymorphisms in Italian patients with primary biliary cirrhosis. J Hepatol 2003, 38:401-6.
27. Liu HY, Deng AM, Zhou Y, Yao DK, Zhong RQ. Analysis of HLA alleles polymorphism in Chinese patients with primary biliary cirrhosis. Hepatobiliary Pancreat Dis Int 2006, 5:129032.
28. Invernitz P, Selmi C, Poli F. Human leukocyte antigen polymorphisms in Italian primary biliary cirrhosis: a multicenter study of 664 patients and 1992 healthy controls. Hepatology 2008, 48:1906-12.
29. Hirschfield GM, Liu X, Xu C. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med 2009, 360:2544-55.
30. Stone J, Wade JA, Cauch-Dudek K. Human leukocyte antigen class II associations in serum antimitochondrial antibodies (AMA)-positive and AMA-negative primary biliary cirrhosis. J Hepatol 2002, 36:8-13.
31. Poupon R, Chazouilleres O, Corpechot C, Chretien Y. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology 2006, 44:85-90.
32. McGinnis MD, Conrad MP, Bouwens AG, Tilanus MG, Kronick MN. Automated, solid-phase sequencing of DRB region genes using T7 sequencing chemistry and dye-labeled primers. Tissue Antigens 1995, 46:173-9.
33. Kimura A, Sasazuki T. Eleventh international histocompatibility workshop reference protocol for the HLA DNA typing technique. HLA 1991 Proceedings of the Eleventh International Histocompatibility Workshop and Conference 1992, 397-418. Tsuji K, Aizawa MSasazuki T. In, eds., Oxford, UK, Oxford University Press
34. Seki T, Ota M, Furuta S. HLA class II molecules and autoimmune hepatitis susceptibility in Japanese patients. Gastroenterology 1992, 103:1041-8.
35. Haruna Y, Miyamoto T, Yasunami R, Kanda T, Fushimi H, Kotoh K. Human leukocyte antigen DRB1*1302 protects against bile duct damage and portal lymphocyte infiltration in patients with chronic hepatitis C. J. 2000, 32:837-42.
36. Reveille JD. The genetic basis of autoantibody production. Autoimmun Rev 2006, 5:389-98.
37. van Gaalen FA, van Aken J, Huizinga TWJ. Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum 2004, 50:2113-21.
38. Szodoray P, Szabo Z, Kapitany A. Anti-citrullinated protein/peptice autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis. Autoimmun Rev 2009
39. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Huizinga TW, Toes RE, de Vries RR. The HLA-DRB1 shared epitope alleles are primary a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arhritis Rheum 2006, 54:1117-21.
40. Kuwana M, Inoko H, Kameda H. Association of human leukocyte antigen class II with autoantibody profiles, but not with disease susceptibility in Japanese patients with systemic sclerosis. Intern Med 1999, 38:336-44.
41. Kuwana M, Okano Y, Kaburaki J, Inoko H. HLA class II genes associated with anticentromere antibody in Japanese patients with systemic sclerosis (scleroderma). Ann Rheum Dis 1995, 54:983-7.
42. Reveille JD, Owerbach D, Goldstein R, Moreda R, Isern RA, Arnett FC. Association of polar amino acids at position 26 of the HLA-DQB1 first domain with the anticentromere autoantibody response in syustemic sclerosis (Scleroderma). J Clin Invest 1992, 89:1208-13.